These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 11029513

  • 21. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
    Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G.
    Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
    [Abstract] [Full Text] [Related]

  • 22. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A.
    Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
    [Abstract] [Full Text] [Related]

  • 23. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [Abstract] [Full Text] [Related]

  • 24. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, Armatis P.
    Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
    [Abstract] [Full Text] [Related]

  • 25. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E.
    Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
    [Abstract] [Full Text] [Related]

  • 26. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
    Gründker C, Ernst J, Reutter MD, Ghadimi BM, Emons G.
    Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
    [Abstract] [Full Text] [Related]

  • 27. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
    Gründker C, Emons G.
    Reprod Biol Endocrinol; 2003 Oct 07; 1():65. PubMed ID: 14594454
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.
    Prostate; 2006 Feb 01; 66(2):200-10. PubMed ID: 16173040
    [Abstract] [Full Text] [Related]

  • 29. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O.
    Arch Gynecol Obstet; 2012 Aug 01; 286(2):437-42. PubMed ID: 22555802
    [Abstract] [Full Text] [Related]

  • 30. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
    Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G.
    Cancer Res; 1995 Feb 15; 55(4):817-22. PubMed ID: 7850795
    [Abstract] [Full Text] [Related]

  • 31. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A.
    J Cancer Res Clin Oncol; 1993 Feb 15; 119(5):273-8. PubMed ID: 8382705
    [Abstract] [Full Text] [Related]

  • 32. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S, Schlotawa L, Günthert AR, Emons G, Gründker C.
    Gynecol Endocrinol; 2008 Jan 15; 24(1):24-9. PubMed ID: 17943530
    [Abstract] [Full Text] [Related]

  • 33. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
    Völker P, Gründker C, Schmidt O, Schulz KD, Emons G.
    Am J Obstet Gynecol; 2002 Feb 15; 186(2):171-9. PubMed ID: 11854630
    [Abstract] [Full Text] [Related]

  • 34. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
    Günthert AR, Gründker C, Hollmann K, Emons G.
    Biochem Biophys Res Commun; 2002 May 31; 294(1):11-5. PubMed ID: 12054733
    [Abstract] [Full Text] [Related]

  • 35. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
    Engel JB, Tinneberg HR, Rick FG, Berkes E, Schally AV.
    Curr Drug Targets; 2016 May 31; 17(5):488-94. PubMed ID: 26951061
    [Abstract] [Full Text] [Related]

  • 36. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN, Liebow C.
    Cancer Res; 2000 Aug 01; 60(15):4194-9. PubMed ID: 10945629
    [Abstract] [Full Text] [Related]

  • 37. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Kahan Z.
    Int J Oncol; 2000 Aug 01; 17(2):367-73. PubMed ID: 10891548
    [Abstract] [Full Text] [Related]

  • 38. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
    Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C, Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV.
    Gynecol Oncol; 2010 Dec 01; 119(3):457-61. PubMed ID: 20828803
    [Abstract] [Full Text] [Related]

  • 39. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1803-9. PubMed ID: 9392622
    [Abstract] [Full Text] [Related]

  • 40. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Nagy A, Schally AV, Emons G.
    Breast Cancer Res Treat; 2004 Oct 03; 87(3):255-64. PubMed ID: 15528968
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.